Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis
Advances in brain imaging have led to a higher incidence of brain metastases (BM) being diagnosed. Stereotactic radiotherapy (SRS), systemic immunotherapy, and targeted drug therapy are commonly used for treating BM. In this study, we summarized the differences in overall survival (OS) between sever...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-03-01
|
| Series: | Open Life Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/biol-2022-0559 |
| _version_ | 1827969111677730816 |
|---|---|
| author | Su Zhou Zhang Li Xue Shaolong Wang Youke Ding Ruining |
| author_facet | Su Zhou Zhang Li Xue Shaolong Wang Youke Ding Ruining |
| author_sort | Su Zhou |
| collection | DOAJ |
| description | Advances in brain imaging have led to a higher incidence of brain metastases (BM) being diagnosed. Stereotactic radiotherapy (SRS), systemic immunotherapy, and targeted drug therapy are commonly used for treating BM. In this study, we summarized the differences in overall survival (OS) between several treatments alone and in combination. We carried out a systematic literature search on Pubmed, EMBASE, and Cochrane Library. Differences in OS associated with Immune checkpoint inhibitors (ICI) alone versus targeted therapy alone and SRS + ICI or ICI alone were evaluated. This analysis was conducted on 11 studies involving 4,154 patients. The comprehensive results of fixed effect model showed that the OS of SRS + ICI group was longer than that of the ICI group (hazard ratio, 1.72; 95% CI: 1.41–2.11; P = 0.22; I
2 = 30%). The combined fixed-effect model showed that the OS time of ICI was longer than that of targeted therapy (hazard ratio, 2.09; 95% CI: 1.37–3.20; P = 0.21; I
2 = 35%). The study had a low risk of bias. In conclusion, our analysis confirmed that immunotherapy alone showed a higher OS benefit in BM patients than targeted therapy alone. The total survival time of patients with SRS combined with ICI was higher than that of patients with single ICI. |
| first_indexed | 2024-04-09T18:32:56Z |
| format | Article |
| id | doaj.art-4ef2639d60924cd3bbab34bc698b9cb2 |
| institution | Directory Open Access Journal |
| issn | 2391-5412 |
| language | English |
| last_indexed | 2024-04-09T18:32:56Z |
| publishDate | 2023-03-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Life Sciences |
| spelling | doaj.art-4ef2639d60924cd3bbab34bc698b9cb22023-04-11T17:07:13ZengDe GruyterOpen Life Sciences2391-54122023-03-011815810.1515/biol-2022-0559Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysisSu Zhou0Zhang Li1Xue Shaolong2Wang Youke3Ding Ruining4Department of Oncology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan 621000, ChinaDepartment of Oncology, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan 621000, ChinaDepartment of Oncology, West China School of Medicine, SCU, Chengdu, ChinaDepartment of Oncology, Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Chengdu, Sichuan, P.R. ChinaDepartment of Oncology, Institute of Drug Clinical Trial/GCP Center, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, ChinaAdvances in brain imaging have led to a higher incidence of brain metastases (BM) being diagnosed. Stereotactic radiotherapy (SRS), systemic immunotherapy, and targeted drug therapy are commonly used for treating BM. In this study, we summarized the differences in overall survival (OS) between several treatments alone and in combination. We carried out a systematic literature search on Pubmed, EMBASE, and Cochrane Library. Differences in OS associated with Immune checkpoint inhibitors (ICI) alone versus targeted therapy alone and SRS + ICI or ICI alone were evaluated. This analysis was conducted on 11 studies involving 4,154 patients. The comprehensive results of fixed effect model showed that the OS of SRS + ICI group was longer than that of the ICI group (hazard ratio, 1.72; 95% CI: 1.41–2.11; P = 0.22; I 2 = 30%). The combined fixed-effect model showed that the OS time of ICI was longer than that of targeted therapy (hazard ratio, 2.09; 95% CI: 1.37–3.20; P = 0.21; I 2 = 35%). The study had a low risk of bias. In conclusion, our analysis confirmed that immunotherapy alone showed a higher OS benefit in BM patients than targeted therapy alone. The total survival time of patients with SRS combined with ICI was higher than that of patients with single ICI.https://doi.org/10.1515/biol-2022-0559brain metastasesimmunotherapyradiotherapymeta-analysisoverall survival |
| spellingShingle | Su Zhou Zhang Li Xue Shaolong Wang Youke Ding Ruining Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis Open Life Sciences brain metastases immunotherapy radiotherapy meta-analysis overall survival |
| title | Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis |
| title_full | Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis |
| title_fullStr | Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis |
| title_full_unstemmed | Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis |
| title_short | Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis |
| title_sort | comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases a systemic review and meta analysis |
| topic | brain metastases immunotherapy radiotherapy meta-analysis overall survival |
| url | https://doi.org/10.1515/biol-2022-0559 |
| work_keys_str_mv | AT suzhou comparisonofimmunotherapycombinedwithstereotacticradiotherapyandtargetedtherapyforpatientswithbrainmetastasesasystemicreviewandmetaanalysis AT zhangli comparisonofimmunotherapycombinedwithstereotacticradiotherapyandtargetedtherapyforpatientswithbrainmetastasesasystemicreviewandmetaanalysis AT xueshaolong comparisonofimmunotherapycombinedwithstereotacticradiotherapyandtargetedtherapyforpatientswithbrainmetastasesasystemicreviewandmetaanalysis AT wangyouke comparisonofimmunotherapycombinedwithstereotacticradiotherapyandtargetedtherapyforpatientswithbrainmetastasesasystemicreviewandmetaanalysis AT dingruining comparisonofimmunotherapycombinedwithstereotacticradiotherapyandtargetedtherapyforpatientswithbrainmetastasesasystemicreviewandmetaanalysis |